StockNews.com Downgrades PDS Biotechnology (NASDAQ:PDSB) to Sell

PDS Biotechnology (NASDAQ:PDSB) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities research analysts also recently weighed in on the company. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

PDS Biotechnology Price Performance

Shares of PDSB stock opened at $3.29 on Friday. The stock’s fifty day simple moving average is $3.25 and its 200 day simple moving average is $3.29. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. The firm has a market cap of $121.14 million, a price-to-earnings ratio of -2.70 and a beta of 1.93. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same period last year, the business posted ($0.37) earnings per share. On average, analysts expect that PDS Biotechnology will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

A number of large investors have recently made changes to their positions in PDSB. Tempus Wealth Planning LLC acquired a new stake in PDS Biotechnology during the second quarter worth approximately $55,000. Ground Swell Capital LLC acquired a new stake in PDS Biotechnology during the second quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in PDS Biotechnology during the second quarter worth approximately $115,000. Squarepoint Ops LLC acquired a new stake in PDS Biotechnology during the second quarter worth approximately $120,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in PDS Biotechnology during the second quarter worth approximately $146,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.